EDG
MCID: GLC011
MIFTS: 49

Galactose Epimerase Deficiency (EDG)

Categories: Blood diseases, Eye diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Galactose Epimerase Deficiency

MalaCards integrated aliases for Galactose Epimerase Deficiency:

Name: Galactose Epimerase Deficiency 58 54 60 38 13 41
Udp-Galactose-4-Epimerase Deficiency 58 77 54 60
Gale Deficiency 58 54 60 56
Galactosemia Type 3 54 60 76
Uridine Diphosphate Galactose-4-Epimerase Deficiency 54 60
Epimerase Deficiency Galactosemia 54 60
Gale-D 54 60
Udpglucose 4-Epimerase Deficiency Disease 74
Epimerase-Deficiency Galactosemia 76
Classical Galactosemia 74
Galactosemia Iii 58
Galactosemia 3 54
Edg 76

Characteristics:

Orphanet epidemiological data:

60
galactose epimerase deficiency
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal;

OMIM:

58
Inheritance:
autosomal recessive

Miscellaneous:
udp-galactose-4-epimerase deficiency in circulating blood cells only ('peripheral' or 'mild' form, usually asymptomatic)


HPO:

33
galactose epimerase deficiency:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Galactose Epimerase Deficiency

OMIM : 58 Epimerase-deficiency galactosemia was originally described as a benign condition in which GALE impairment is restricted to circulating red and white blood cells (Gitzelmann, 1972). Fibroblasts, liver, phytohemagglutinin-stimulated leukocyes, and Epstein Barr virus-transformed lymphoblasts from these patients all demonstrated normal or near-normal levels of GALE, leading to the designation 'peripheral' (or 'isolated') epimerase deficiency. A second form of epimerase deficiency became apparent in which a patient, despite normal GALT activity, presented with symptoms reminiscent of classic galactosemia and demonstrated severely impaired GALE activity in both red blood cells and fibroblasts (Holton et al., 1981). This form was designated 'generalized' epimerase deficiency. Openo et al. (2006) demonstrated that epimerase deficiency is in fact not a binary condition but is, rather, a continuum disorder. GALE encodes the third enzyme in the Leloir pathway of galactose metabolism. Galactosemia I is classic galactosemia (230400), caused by deficiency of the second enzyme in the Leloir pathway, galactose-1-phosphate uridylyl-transferase (GALT; 606999). Galactosemia II (230200) is caused by deficiency of the first enzyme in the Leloir pathway, galactokinase (GALK; 604313). (230350)

MalaCards based summary : Galactose Epimerase Deficiency, also known as udp-galactose-4-epimerase deficiency, is related to galactosemia and epimerase deficiency galactosemia, and has symptoms including vomiting, diarrhea and icterus. An important gene associated with Galactose Epimerase Deficiency is GALE (UDP-Galactose-4-Epimerase), and among its related pathways/superpathways are Galactose metabolism and Glycosaminoglycan metabolism. The drugs Neurotransmitter Agents and Excitatory Amino Acids have been mentioned in the context of this disorder. Affiliated tissues include liver, breast and heart, and related phenotypes are intellectual disability and muscular hypotonia

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 79238Disease definitionGalactose epimerase deficiency is a very rare, moderate to severe form of galactosemia (see this term) characterized by moderate to severe signs of impaired galactose metabolism.EpidemiologyOverall prevalence is not known but the disorder is thought to be very rare. Annual incidence is not known.Clinical descriptionThe disorder represents a continuum from peripheral to generalized states with corresponding disease severity. When ingesting breast milk or lactose-containing formula, patients may develop hypotonia, poor feeding, vomiting, weight loss, jaundice, hepatomegaly, splenomegaly, liver disorders, aminoaciduria, impaired growth, cataracts and cognitive deficiency. In severe cases, the disease can be life-threatening.EtiologyGalactose epimerase deficiency is caused by mutations in the GALE gene (1p36) encoding the UDP-galactose 4-epimerase enzyme.Genetic counselingGalactose epimerase deficiency is inherited in an autosomal recessive manner.PrognosisOccurrence of these symptoms can be resolved or prevented by implementing a galactose-restricted diet.Visit the Orphanet disease page for more resources.

UniProtKB/Swiss-Prot : 76 Epimerase-deficiency galactosemia: Clinical features include early-onset cataracts, liver damage, deafness and mental retardation. There are two clinically distinct forms of EDG. (1) A benign, or 'peripheral' form with no detectable GALE activity in red blood cells and characterized by mild symptoms. Some patients may suffer no symptoms beyond raised levels of galactose-1-phosphate in the blood. (2) A much rarer 'generalized' form with undetectable levels of GALE activity in all tissues and resulting in severe features such as restricted growth and mental development.

Wikipedia : 77 Galactosemia (British galactosaemia, from Greek γαλακτόζη + αίμα, meaning galactose + blood,... more...

Related Diseases for Galactose Epimerase Deficiency

Diseases related to Galactose Epimerase Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 473)
# Related Disease Score Top Affiliating Genes
1 galactosemia 32.1 GALE GALK1 GALT
2 epimerase deficiency galactosemia 30.8 GALE GALK1 GALT
3 generalized galactose epimerase deficiency 12.4
4 erythrocyte galactose epimerase deficiency 12.4
5 melanoma 11.4
6 lentigines 11.3
7 developmental dysplasia of the hip 1 11.3
8 exudative vitreoretinopathy 11.2
9 spondylometaphyseal dysplasia, corner fracture type 11.1
10 gillespie syndrome 11.1
11 nail disorder, nonsyndromic congenital, 8 11.1
12 cataract 1, multiple types 10.9
13 kabuki syndrome 1 10.9
14 nail disorder, nonsyndromic congenital, 2 10.9
15 lymphedema-distichiasis syndrome 10.9
16 nail disorder, nonsyndromic congenital, 5 10.9
17 lipoid proteinosis of urbach and wiethe 10.9
18 cataract 10, multiple types 10.9
19 cataract 14, multiple types 10.9
20 cataract 23, multiple types 10.9
21 uvulitis 10.9
22 tuberculoid leprosy 10.9
23 breast cyst 10.9
24 hordeolum externum 10.9
25 acral lentiginous melanoma 10.9
26 aphthous stomatitis 10.9
27 hordeolum 10.9
28 ichthyosis linearis circumflexa 10.9
29 leukoplakia 10.9
30 mitral valve insufficiency 10.6
31 cataract 10.4
32 tricuspid valve insufficiency 10.4
33 allergic encephalomyelitis 10.2
34 autoimmune disease 10.2
35 rere-related disorders 10.1
36 blood group, gerbich system 10.1
37 systemic lupus erythematosus 10.0
38 lupus erythematosus 10.0
39 rapidly involuting congenital hemangioma 10.0
40 arthritis 10.0
41 hepatitis 10.0
42 pulmonary hypertension 10.0
43 macular holes 10.0
44 neutrophil migration 9.9
45 pulmonary alveolar microlithiasis 9.9
46 malaria 9.9
47 intraocular pressure quantitative trait locus 9.9
48 congestive heart failure 9.9
49 inflammatory bowel disease 9.9
50 thrombosis 9.9

Graphical network of the top 20 diseases related to Galactose Epimerase Deficiency:



Diseases related to Galactose Epimerase Deficiency

Symptoms & Phenotypes for Galactose Epimerase Deficiency

Human phenotypes related to Galactose Epimerase Deficiency:

60 33 (show all 21)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intellectual disability 60 33 hallmark (90%) Very frequent (99-80%) HP:0001249
2 muscular hypotonia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001252
3 nausea and vomiting 60 33 hallmark (90%) Very frequent (99-80%) HP:0002017
4 cataract 60 33 hallmark (90%) Very frequent (99-80%) HP:0000518
5 global developmental delay 60 33 hallmark (90%) Very frequent (99-80%) HP:0001263
6 splenomegaly 60 33 hallmark (90%) Very frequent (99-80%) HP:0001744
7 hepatomegaly 60 33 hallmark (90%) Very frequent (99-80%) HP:0002240
8 aminoaciduria 60 33 hallmark (90%) Very frequent (99-80%) HP:0003355
9 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
10 feeding difficulties 60 33 hallmark (90%) Very frequent (99-80%) HP:0011968
11 growth delay 60 33 hallmark (90%) Very frequent (99-80%) HP:0001510
12 jaundice 60 33 hallmark (90%) Very frequent (99-80%) HP:0000952
13 impairment of galactose metabolism 60 33 hallmark (90%) Very frequent (99-80%) HP:0004915
14 failure to thrive 33 HP:0001508
15 delayed speech and language development 33 HP:0000750
16 sensorineural hearing impairment 33 HP:0000407
17 vomiting 33 HP:0002013
18 generalized hypotonia 33 HP:0001290
19 delayed gross motor development 33 HP:0002194
20 galactosuria 33 HP:0012023
21 hypergalactosemia 33 HP:0012024

Symptoms via clinical synopsis from OMIM:

58
Growth Other:
failure to thrive

Abdomen Liver:
hepatomegaly

Laboratory Abnormalities:
aminoaciduria
galactosuria
galactosemia
udp-galactose-4-epimerase deficiency in all cells ('generalized' or 'severe' form)

Neurologic Central Nervous System:
hypotonia
mental retardation
language delay
developmental delay, gross motor
cognitive delay

Abdomen Spleen:
splenomegaly

Abdomen Gastrointestinal:
vomiting

Skin Nails Hair Skin:
jaundice

Head And Neck Ears:
deafness, sensorineural

Clinical features from OMIM:

230350

UMLS symptoms related to Galactose Epimerase Deficiency:


vomiting, diarrhea, icterus

GenomeRNAi Phenotypes related to Galactose Epimerase Deficiency according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased IL-8 secretion GR00386-A-2 8.8 GALE GALK1 GALT

Drugs & Therapeutics for Galactose Epimerase Deficiency

Drugs for Galactose Epimerase Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Neurotransmitter Agents Phase 2
2 Excitatory Amino Acids Phase 2
3 Excitatory Amino Acid Agonists Phase 2
4 N-Methylaspartate Phase 2
5 arginine Phase 2
6 Aspartic Acid Phase 2
7 Hormones Not Applicable
8 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
9 Follicle Stimulating Hormone Not Applicable
10 Hormone Antagonists Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Effect of Arginine on Classic Galactosemia Completed NCT03580122 Phase 2 Arginine Aspartate
2 Inactive FSH in Galactosemia Unknown status NCT00619333 Not Applicable follitropin and lutropin
3 Glycosylation in Patients With Galactosaemia Completed NCT02218632 Not Applicable
4 Intervention and Outcomes in Duarte Galactosemia Completed NCT02519504
5 Pregnancy Chances in Classic Galactosemia Completed NCT02091128
6 The Early History of Universal Screening for Metabolic Disorders Completed NCT00309400
7 Preventing Speech and Language Disorders in Children With Classic Galactosemia Recruiting NCT03838016 Not Applicable
8 Retrospective Study of Adult Patients With Inborn Errors of Metabolism in Switzerland Recruiting NCT03534752

Search NIH Clinical Center for Galactose Epimerase Deficiency

Genetic Tests for Galactose Epimerase Deficiency

Anatomical Context for Galactose Epimerase Deficiency

MalaCards organs/tissues related to Galactose Epimerase Deficiency:

42
Liver, Breast, Heart, Lung, Thyroid, Bone, Eye

Publications for Galactose Epimerase Deficiency

Articles related to Galactose Epimerase Deficiency:

# Title Authors Year
1
Galactose Epimerase Deficiency: Expanding the Phenotype. ( 28247339 )
2017
2
A first case report of UDP-galactose-4'-epimerase deficiency in China: genotype and phenotype. ( 26565537 )
2016
3
Human UDP-galactose 4' epimerase (GALE) gene and identification of five missense mutations in patients with epimerase-deficiency galactosemia. ( 9538513 )
1998
4
Characterization of two mutations associated with epimerase-deficiency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase. ( 9326324 )
1997
5
UDP galactose-4-epimerase deficiency in a 5.5-year-old girl with unilateral cataract. ( 8295413 )
1993
6
Detection of UDP-galactose-4-epimerase deficiency in a galactosemia screening program. ( 7318169 )
1981
7
A new mass screening method of detecting UDP-galactose-4-epimerase deficiency. ( 7404573 )
1980
8
Reversal of UDP-galactose 4-epimerase deficiency of human leukocytes in culture. ( 1748 )
1975

Variations for Galactose Epimerase Deficiency

UniProtKB/Swiss-Prot genetic disease variations for Galactose Epimerase Deficiency:

76 (show all 16)
# Symbol AA change Variation ID SNP ID
1 GALE p.Asn34Ser VAR_002539 rs121908046
2 GALE p.Gly90Glu VAR_002540 rs28940882
3 GALE p.Asp103Gly VAR_002541 rs28940883
4 GALE p.Leu183Pro VAR_002543 rs121908045
5 GALE p.Lys257Arg VAR_002544 rs28940884
6 GALE p.Leu313Met VAR_002545 rs3180383
7 GALE p.Gly319Glu VAR_002546 rs28940885
8 GALE p.Val94Met VAR_010058 rs121908047
9 GALE p.Ala25Val VAR_037733 rs143177292
10 GALE p.Arg40Cys VAR_037734 rs144492228
11 GALE p.Asp69Glu VAR_037735 rs126169796
12 GALE p.Glu165Lys VAR_037736 rs528467258
13 GALE p.Arg169Trp VAR_037737 rs137853859
14 GALE p.Arg239Trp VAR_037738 rs137853860
15 GALE p.Gly302Asp VAR_037739 rs137853861
16 GALE p.Arg335His VAR_037740 rs368637540

ClinVar genetic disease variations for Galactose Epimerase Deficiency:

6 (show top 50) (show all 74)
# Gene Variation Type Significance SNP ID Assembly Location
1 GALE NM_000403.3(GALE): c.548T> C (p.Leu183Pro) single nucleotide variant Pathogenic rs121908045 GRCh37 Chromosome 1, 24123618: 24123618
2 GALE NM_000403.3(GALE): c.548T> C (p.Leu183Pro) single nucleotide variant Pathogenic rs121908045 GRCh38 Chromosome 1, 23797128: 23797128
3 GALE NM_000403.3(GALE): c.101A> G (p.Asn34Ser) single nucleotide variant Pathogenic rs121908046 GRCh37 Chromosome 1, 24125397: 24125397
4 GALE NM_000403.3(GALE): c.101A> G (p.Asn34Ser) single nucleotide variant Pathogenic rs121908046 GRCh38 Chromosome 1, 23798907: 23798907
5 GALE NM_000403.3(GALE): c.269G> A (p.Gly90Glu) single nucleotide variant Pathogenic rs28940882 GRCh37 Chromosome 1, 24124689: 24124689
6 GALE NM_000403.3(GALE): c.269G> A (p.Gly90Glu) single nucleotide variant Pathogenic rs28940882 GRCh38 Chromosome 1, 23798199: 23798199
7 GALE NM_001008216.1(GALE): c.308A> G (p.Asp103Gly) single nucleotide variant Pathogenic rs28940883 GRCh37 Chromosome 1, 24124650: 24124650
8 GALE NM_001008216.1(GALE): c.308A> G (p.Asp103Gly) single nucleotide variant Pathogenic rs28940883 GRCh38 Chromosome 1, 23798160: 23798160
9 GALE NM_000403.3(GALE): c.770A> G (p.Lys257Arg) single nucleotide variant Conflicting interpretations of pathogenicity, other rs28940884 GRCh37 Chromosome 1, 24123212: 24123212
10 GALE NM_000403.3(GALE): c.770A> G (p.Lys257Arg) single nucleotide variant Conflicting interpretations of pathogenicity, other rs28940884 GRCh38 Chromosome 1, 23796722: 23796722
11 GALE NM_001008216.1(GALE): c.937C> A (p.Leu313Met) single nucleotide variant Pathogenic rs3180383 GRCh37 Chromosome 1, 24122692: 24122692
12 GALE NM_001008216.1(GALE): c.937C> A (p.Leu313Met) single nucleotide variant Pathogenic rs3180383 GRCh38 Chromosome 1, 23796202: 23796202
13 GALE NM_000403.3(GALE): c.956G> A (p.Gly319Glu) single nucleotide variant other rs28940885 GRCh37 Chromosome 1, 24122673: 24122673
14 GALE NM_000403.3(GALE): c.956G> A (p.Gly319Glu) single nucleotide variant other rs28940885 GRCh38 Chromosome 1, 23796183: 23796183
15 GALE NM_000403.3(GALE): c.280G> A (p.Val94Met) single nucleotide variant Pathogenic/Likely pathogenic rs121908047 GRCh37 Chromosome 1, 24124678: 24124678
16 GALE NM_000403.3(GALE): c.280G> A (p.Val94Met) single nucleotide variant Pathogenic/Likely pathogenic rs121908047 GRCh38 Chromosome 1, 23798188: 23798188
17 GALE NM_000403.3(GALE): c.505C> T (p.Arg169Trp) single nucleotide variant Pathogenic rs137853859 GRCh37 Chromosome 1, 24124208: 24124208
18 GALE NM_000403.3(GALE): c.505C> T (p.Arg169Trp) single nucleotide variant Pathogenic rs137853859 GRCh38 Chromosome 1, 23797718: 23797718
19 GALE NM_000403.3(GALE): c.715C> T (p.Arg239Trp) single nucleotide variant Likely pathogenic rs137853860 GRCh37 Chromosome 1, 24123267: 24123267
20 GALE NM_000403.3(GALE): c.715C> T (p.Arg239Trp) single nucleotide variant Likely pathogenic rs137853860 GRCh38 Chromosome 1, 23796777: 23796777
21 GALE NM_000403.3(GALE): c.905G> A (p.Gly302Asp) single nucleotide variant Pathogenic rs137853861 GRCh37 Chromosome 1, 24122724: 24122724
22 GALE NM_000403.3(GALE): c.905G> A (p.Gly302Asp) single nucleotide variant Pathogenic rs137853861 GRCh38 Chromosome 1, 23796234: 23796234
23 GALE NM_000403.3(GALE): c.709+14C> G single nucleotide variant Benign/Likely benign rs6692104 GRCh37 Chromosome 1, 24123352: 24123352
24 GALE NM_000403.3(GALE): c.709+14C> G single nucleotide variant Benign/Likely benign rs6692104 GRCh38 Chromosome 1, 23796862: 23796862
25 GALE NM_000403.3(GALE): c.873+13G> A single nucleotide variant Benign rs760941 GRCh37 Chromosome 1, 24122986: 24122986
26 GALE NM_000403.3(GALE): c.873+13G> A single nucleotide variant Benign rs760941 GRCh38 Chromosome 1, 23796496: 23796496
27 GALE NM_000403.3(GALE): c.912G> A (p.Val304=) single nucleotide variant Conflicting interpretations of pathogenicity rs143694860 GRCh37 Chromosome 1, 24122717: 24122717
28 GALE NM_000403.3(GALE): c.912G> A (p.Val304=) single nucleotide variant Conflicting interpretations of pathogenicity rs143694860 GRCh38 Chromosome 1, 23796227: 23796227
29 GALE NM_000403.3(GALE): c.97G> A (p.Asp33Asn) single nucleotide variant Uncertain significance rs727503945 GRCh37 Chromosome 1, 24125401: 24125401
30 GALE NM_000403.3(GALE): c.97G> A (p.Asp33Asn) single nucleotide variant Uncertain significance rs727503945 GRCh38 Chromosome 1, 23798911: 23798911
31 GALE NM_000403.3(GALE): c.*327A> T single nucleotide variant Uncertain significance rs535702110 GRCh38 Chromosome 1, 23795622: 23795622
32 GALE NM_000403.3(GALE): c.*327A> T single nucleotide variant Uncertain significance rs535702110 GRCh37 Chromosome 1, 24122112: 24122112
33 GALE NM_000403.3(GALE): c.955G> C (p.Gly319Arg) single nucleotide variant Uncertain significance rs752384408 GRCh38 Chromosome 1, 23796184: 23796184
34 GALE NM_000403.3(GALE): c.955G> C (p.Gly319Arg) single nucleotide variant Uncertain significance rs752384408 GRCh37 Chromosome 1, 24122674: 24122674
35 GALE NM_000403.3(GALE): c.648G> A (p.Ala216=) single nucleotide variant Uncertain significance rs144723215 GRCh38 Chromosome 1, 23796937: 23796937
36 GALE NM_000403.3(GALE): c.648G> A (p.Ala216=) single nucleotide variant Uncertain significance rs144723215 GRCh37 Chromosome 1, 24123427: 24123427
37 GALE NM_000403.3(GALE): c.506G> A (p.Arg169Gln) single nucleotide variant Uncertain significance rs140878602 GRCh38 Chromosome 1, 23797717: 23797717
38 GALE NM_000403.3(GALE): c.506G> A (p.Arg169Gln) single nucleotide variant Uncertain significance rs140878602 GRCh37 Chromosome 1, 24124207: 24124207
39 GALE NM_000403.3(GALE): c.450G> A (p.Thr150=) single nucleotide variant Uncertain significance rs566884215 GRCh38 Chromosome 1, 23797773: 23797773
40 GALE NM_000403.3(GALE): c.450G> A (p.Thr150=) single nucleotide variant Uncertain significance rs566884215 GRCh37 Chromosome 1, 24124263: 24124263
41 GALE NM_000403.3(GALE): c.423C> T (p.Tyr141=) single nucleotide variant Uncertain significance rs138518245 GRCh37 Chromosome 1, 24124290: 24124290
42 GALE NM_000403.3(GALE): c.423C> T (p.Tyr141=) single nucleotide variant Uncertain significance rs138518245 GRCh38 Chromosome 1, 23797800: 23797800
43 GALE NM_000403.3(GALE): c.873+13_873+14insA insertion Uncertain significance rs765063773 GRCh38 Chromosome 1, 23796495: 23796496
44 GALE NM_000403.3(GALE): c.873+13_873+14insA insertion Uncertain significance rs765063773 GRCh37 Chromosome 1, 24122985: 24122986
45 GALE NM_000403.3(GALE): c.647C> T (p.Ala216Val) single nucleotide variant Uncertain significance rs542192037 GRCh38 Chromosome 1, 23796938: 23796938
46 GALE NM_000403.3(GALE): c.647C> T (p.Ala216Val) single nucleotide variant Uncertain significance rs542192037 GRCh37 Chromosome 1, 24123428: 24123428
47 GALE NM_000403.3(GALE): c.369G> A (p.Gly123=) single nucleotide variant Uncertain significance rs138148991 GRCh38 Chromosome 1, 23797854: 23797854
48 GALE NM_000403.3(GALE): c.369G> A (p.Gly123=) single nucleotide variant Uncertain significance rs138148991 GRCh37 Chromosome 1, 24124344: 24124344
49 GALE NM_000403.3(GALE): c.-161C> G single nucleotide variant Uncertain significance rs566996145 GRCh38 Chromosome 1, 23800471: 23800471
50 GALE NM_000403.3(GALE): c.-161C> G single nucleotide variant Uncertain significance rs566996145 GRCh37 Chromosome 1, 24126961: 24126961

Expression for Galactose Epimerase Deficiency

Search GEO for disease gene expression data for Galactose Epimerase Deficiency.

Pathways for Galactose Epimerase Deficiency

Pathways related to Galactose Epimerase Deficiency according to KEGG:

38
# Name Kegg Source Accession
1 Galactose metabolism hsa00052

GO Terms for Galactose Epimerase Deficiency

Biological processes related to Galactose Epimerase Deficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.43 GALE GALK1 GALT
2 galactose catabolic process via UDP-galactose GO:0033499 9.16 GALK1 GALT
3 galactose metabolic process GO:0006012 9.13 GALE GALK1 GALT
4 galactose catabolic process GO:0019388 8.8 GALE GALK1 GALT

Sources for Galactose Epimerase Deficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....